KalVista Pharmaceuticals (NASDAQ:KALV) CEO Sells $107,623.44 in Stock

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) CEO Benjamin Palleiko sold 6,693 shares of the company’s stock in a transaction on Monday, March 9th. The stock was sold at an average price of $16.08, for a total value of $107,623.44. Following the sale, the chief executive officer directly owned 451,815 shares in the company, valued at $7,265,185.20. This represents a 1.46% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

KalVista Pharmaceuticals Trading Up 6.6%

Shares of NASDAQ KALV traded up $1.14 during mid-day trading on Tuesday, hitting $18.44. The company had a trading volume of 1,664,127 shares, compared to its average volume of 690,285. KalVista Pharmaceuticals, Inc. has a 1-year low of $9.23 and a 1-year high of $19.00. The company has a quick ratio of 7.21, a current ratio of 7.22 and a debt-to-equity ratio of 8.18. The business’s 50-day simple moving average is $15.66 and its 200 day simple moving average is $14.19.

Institutional Investors Weigh In On KalVista Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Seven Fleet Capital Management LP purchased a new position in shares of KalVista Pharmaceuticals during the fourth quarter worth approximately $782,000. Invesco Ltd. increased its stake in KalVista Pharmaceuticals by 23.1% in the fourth quarter. Invesco Ltd. now owns 77,864 shares of the specialty pharmaceutical company’s stock valued at $1,258,000 after purchasing an additional 14,621 shares during the period. XTX Topco Ltd purchased a new stake in shares of KalVista Pharmaceuticals in the fourth quarter valued at about $428,000. Vestal Point Capital LP raised its holdings in shares of KalVista Pharmaceuticals by 152.0% in the fourth quarter. Vestal Point Capital LP now owns 1,890,000 shares of the specialty pharmaceutical company’s stock valued at $30,524,000 after buying an additional 1,140,000 shares during the last quarter. Finally, Virtus Investment Advisers LLC boosted its stake in shares of KalVista Pharmaceuticals by 364.9% during the fourth quarter. Virtus Investment Advisers LLC now owns 40,414 shares of the specialty pharmaceutical company’s stock worth $653,000 after buying an additional 31,721 shares during the period.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on the stock. Citizens Jmp reduced their price objective on shares of KalVista Pharmaceuticals from $29.00 to $28.00 and set a “market outperform” rating on the stock in a report on Tuesday, November 11th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of KalVista Pharmaceuticals in a report on Thursday, January 22nd. HC Wainwright raised their target price on KalVista Pharmaceuticals from $27.00 to $37.00 and gave the stock a “buy” rating in a research report on Friday, January 9th. Needham & Company LLC raised their price objective on shares of KalVista Pharmaceuticals from $28.00 to $32.00 and gave the stock a “buy” rating in a report on Tuesday, January 6th. Finally, TD Cowen restated a “buy” rating on shares of KalVista Pharmaceuticals in a research report on Wednesday, December 3rd. Seven analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $29.40.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.